Ibogaine HCl (DMX-1002) for OUD

DemeRx are planning to conduct a Phase II proof of concept study investigating the effects of their DMX-1002 formulation for the treatment of Opioid Use Disorder.

DMX-1002 is an ibogaine formulation.

DemeRx has received approval from the UK Medicines and Healthcare products Regulatory Agency to commence enrolment for a Phase I/IIa clinical trial.

Topic Addiction Opioid Use Disorder
Compound Ibogaine
Country United Kingdom
Visit trial
Status Planned
Results Published No
Design Open
Type Interventional
Generation Second
Sex All
Therapy No

Trial Details



Trial Number

Sponsors & Collaborators

DemeRx
DemeRx is a subsidiary of atai that aims to develop ibogaine for Opioid Use Disorder.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.